GlaxoSmithKline Pharmaceuticals Limited · NSE:GLAXO
GlaxoSmithKline Pharmaceuticals — FY2012 Earnings Presentation
9 slides from GlaxoSmithKline Pharmaceuticals's earnings presentation, Apr 24, 2013
Slide 1: Results 2012
e csk An Kline Results 2012
Slide 2: Statement of Profit & Loss
Statement of Profit & LossINR Mn 2012 2011 Gr % Sale of products (net) 25,999 23,380 11.2% Other operating revenue 304 378 Revenue from operations 26,303 23,759 Other Income 1,935 1,596 21.2% Total Revenue 28,238 25,355 Cost of materials consumed 4,378 4,312 Purchases of traded goods 6,075 5,334 (In
Slide 3: Financial Summary
Financial Summary INR Mn Q4 2012 2012 Amt Gr % Amt Gr % Net Sales 6,567 16.0 25,999 11.2 Pharma 6,257 15.9 24,803 12.5 Iodex 256 7.6 1,000 3.5 Exports 54 196 (46.0) Total Materials consumed 2,803 20.7 10,979 20.8 % to Sales 43% 42% Staff Cost 769 2,955 % to Sales 12% 11% Other Opex (Incl depreciatio
Slide 4: Performance Across Business Verticals 2012 vs 2011
Performance Across Business Verticals 2012 vs 2011 Vaccines 34% Specialties +16% Mass Specialty +10% Derma+ Oth spl 17% +22% Mass Markets 7%
Slide 5: Creating a broader portfolio of potential high value assets
Creating a broader portfolio of potential high value assets New products contributions to growth in 2012 30% New Products contributions to Total Rx Sales 6% 2010 2011 2012
Slide 6: Exceptional Items
Exceptional Items INR Mn 2012 - Thane VRS 911 - Thane MS VRS commitment/restructuring 110 - Thane site decommissioning 127 - Thane Operating costs 198 - Actuarial Loss on Employee benefits 135 1,482 Net of Tax 999
Slide 7: Cash Flow
CASH FLOW INR Mn 2012 Profit before taxation and exceptional items 9,948 Depreciation and other non-operating activities (1,742) Operating profit before working capital changes 8,206 (Increase)/Decrease in: Inventories 471 Trade and other receivables (510) Trade payables and other liabilities 380 Ca
Slide 8: Financial performance
Financial performance EPS and Book Value per share (INR) 40.7 40.7 68.6 ` 59.6 68.2 R ONW 52.9 39.9 39.8 R OCE ` 50.8 39.5 34.5 279 285 32.8 228 31.5 208 30.9 182 30.6 B ook value 2008 2009 2010 2011 2012 2008 2009 2010 2011 2012 Dividend Payout (INR) 70% 73% 68% 18 18 49% 59% 45 50 45% 40 30 18 22
Slide 9: Thank you
Thank you
GlaxoSmithKline Pharmaceuticals — FY2012 Earnings Presentation on 6ix